Skip to search formSkip to main contentSkip to account menu

fluticasone / salmeterol

Known as: fluticasone-salmeterol, FLUTICASONE/SALMETEROL, Fluticasone Salmeterol Combination 
National Institutes of Health

Related topics

Related topics

3 relations
Fluticasone Propionate, Salmeterol Xinafoate Drug Combinationfluticasonesalmeterol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.
BACKGROUND Asthma is characterised by chronic inflammation of the airways and recurrent exacerbations with wheezing, chest… 
Review
2007
Review
2007
Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.
BACKGROUND Long-acting beta-agonists and inhaled corticosteroids have both been recommended in guidelines for the treatment of… 
Highly Cited
2005
Highly Cited
2005
Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists.
Greater clinical benefit in controlling the symptoms of asthma is frequently observed through combining moderate doses of inhaled… 
Highly Cited
2004
Highly Cited
2004
Lactose Surface Modification by Decantation: Are Drug-Fine Lactose Ratios the Key to Better Dispersion of Salmeterol Xinafoate from Lactose-Interactive Mixtures?
AbstractPurpose. The role of fine lactose in the dispersion of salmeterol xina- foate (SX) from lactose mixtures was studied by… 
Highly Cited
2003
Highly Cited
2003
The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.
STUDY OBJECTIVES To compare the efficacy and safety of the inhaled corticosteroid fluticasone propionate (FP) and the inhaled… 
Highly Cited
2003
Highly Cited
2003
Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.
We evaluated whether montelukast conferred additive effects in patients with asthma receiving fluticasone/salmeterol (FP/SM… 
Highly Cited
2001
Highly Cited
2001
Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.
AIMS To determine the basal pharmacokinetics, lung uptake and plasma cortisol suppression for two commonly prescribed inhaled… 
Highly Cited
1999
Highly Cited
1999
Ligand‐induced differentiation of glucocorticoid receptor (GR) trans‐repression and transactivation: preferential targetting of NF‐κB and lack of I‐κB involvement
Glucocorticoids are highly effective in controlling chronic inflammatory diseases, such as asthma and rheumatoid arthritis, but… 
Highly Cited
1996
Highly Cited
1996
Sustained Activation of a G Protein-coupled Receptor via “Anchored” Agonist Binding
An inherent therapeutic limitation of many G protein-coupled receptor agonists is a short duration of action due to rapid… 
Highly Cited
1995
Highly Cited
1995
Salmeterol xinafoate in children on high dose inhaled steroids.
BACKGROUND Current UK and international guidelines on asthma management recommend that, in pediatric patients still symptomatic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)